Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis.

Trial Profile

Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Fracture; Osteoporosis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Oct 2010 Results presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research.
    • 03 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top